Trial Design, Treatment Options Spotlighted in Xylazine Conference - MedPageToday

Longer observation periods following treatment and safety considerations for chronic and frequent users are among the many research issues about xylazine-laced fentanyl that need addressing, Rachel Wightman, MD, said at a meeting on mitigating risks from human xylazine exposure sponsored by the Reagan-Udall Foundation.

Read more

Reagan-Udall Foundation To Propose FDA Rebuild Trust To Combat Misinformation - Inside Health Policy

The Reagan-Udall Foundation is set to release a major new report Thursday (Oct. 5) that will suggest FDA combat health misinformation surrounding FDA-regulated products by rebuilding longstanding trust in the agency instead of reacting to issues case-by-case – a report requested by FDA Commissioner Robert Califf to help solve what he has said is major problem ensnarling the agency’s public health mission

Read more